DSP Development

Efficiency is key for a good downstream process : to consistently obtain a pure and high quality product, while recovering as much target protein as possible. Celonic has set up a downstream platform process for antibodies, recovering more than 75 % of the target protein. This saves considerable development time and costs. In addition, our experience in process development for non-antibody products enables us to maximize the recovery rate during platform adaptation.      

  • Adaption of state-of-the-art processes for mABs
  • Process development for non-antibody products
  • Process intermediate stability studies
  • Virus clearance studies
  • Extensive experience in purifying products from inhouse CHOvolution™ and the human GEX® cell line